Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Government-private Sector Dialogue Begins
February 5, 2007
- Kansai Bio-Cluster Is No. 4 in the World: Prof. Morishita
February 5, 2007
- PM Abe Calls For Strategic Support of Pharma Industry in Policy Speech
February 5, 2007
- REGULATORY NEWS IN BRIEF
February 5, 2007
- Course and Strategy for Japanese Economy Approved by Cabinet
February 5, 2007
- Mochida Aims to Become Specialty Pharma Focused in 4 Fields
February 5, 2007
- COMMENTARY From Convoy System to Competition
February 5, 2007
- Health Minister Yanagisawa Sees Need for Gov't to Prevent Buy-outs
February 5, 2007
- Pfizer Embarks on Major Restructuring
February 5, 2007
- Council Calls For Rapid Development of Alemtuzumab, Talc
February 5, 2007
- TOPICS 2 articles
February 5, 2007
- Add'l Indications Recommended for Valtrex, Glivec
February 5, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 5, 2007
- Pfizer Japan, Astellas Announce Approval of Celecox
February 5, 2007
- MEXT to Strengthen Anticancer Efforts in FY2007
February 5, 2007
- New Industry Vision to Focus on Environment for Drug Discovery: EAD Director
February 5, 2007
- Saiseikai Group to Initiate Study in Preparation for Joint Purchasing
February 5, 2007
- Global Companies Move toClose Research Lab in Japan
February 5, 2007
- MEDICAL DEVICE NEWS IN BRIEF
February 5, 2007
- Astellas, Kirin Tie Up for Fully Human Monoclonal Antibody
February 5, 2007
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…